echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Ascent Pharmaceuticals and Cinda Biotech reached a strategic cooperation of US$245 million

    Ascent Pharmaceuticals and Cinda Biotech reached a strategic cooperation of US$245 million

    • Last Update: 2021-08-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of July 14, Cinda Biological released an announcement stating that it will carry out a multi-level strategic cooperation with Yasheng Pharmaceutical to jointly commercialize the third-generation BCR-ABL inhibitor HQP1351 and provide the CD20 antibody Dabohua (rituximab).


    On the evening of July 14, Cinda Biological released an announcement stating that it will carry out a multi-level strategic cooperation with Yasheng Pharmaceutical to jointly commercialize the third-generation BCR-ABL inhibitor HQP1351 and provide the CD20 antibody Dabohua (rituximab).
    Injection) and CD47 antibody IB188 (letaplimab) and Bcl-2 inhibitor APG-2575 for clinical development
    .
    In addition, in view of the growth potential of Yasheng Pharmaceutical, Cinda Bio will subscribe for new shares and warrants from Yasheng Pharmaceutical
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.